生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐

智通財經

昨天

【生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐】智通財經APP獲悉，BioNTech(BNTX.US)周一表示，一項後期臨床試驗顯示，其候選藥物gotistobart在一種特定類型肺癌中，較標準治療帶來具有臨床意義的總生存期獲益。公司稱，該試驗為PRESERVE-003 III期臨床試驗，納入的是在接受既往免疫治療和化療後疾病仍出現進展的鱗狀非小細胞肺癌患者;與標準治療化療相比，gotistobart使生存期幾乎翻倍。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2667570696"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667570696\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667570696?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-14 18:26","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2667570696","market":"us","top_or_hot":-1,"title":"生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐】</b>智通財經APP獲悉，BioNTech(BNTX.US)周一表示，一項後期臨床試驗顯示，其候選藥物gotistobart在一種特定類型肺癌中，較標準治療帶來具有臨床意義的總生存期獲益。公司稱，該試驗為PRESERVE-003 \n\nIII期臨床試驗，納入的是在接受既往免疫治療和化療後疾病仍出現進展的鱗狀非小細胞肺癌患者;與標準治療化療相比，gotistobart使生存期幾乎翻倍。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-09-14 18:26</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐】</b>智通財經APP獲悉，BioNTech(BNTX.US)周一表示，一項後期臨床試驗顯示，其候選藥物gotistobart在一種特定類型肺癌中，較標準治療帶來具有臨床意義的總生存期獲益。公司稱，該試驗為PRESERVE-003 \n\nIII期臨床試驗，納入的是在接受既往免疫治療和化療後疾病仍出現進展的鱗狀非小細胞肺癌患者;與標準治療化療相比，gotistobart使生存期幾乎翻倍。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2667570696","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667570696","pubTimestamp":1789381582,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐】智通財經APP獲悉，BioNTech(BNTX.US)周一表示，一項後期臨床","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","CANC":"TEMA ONCOLOGY ETF","BNTX":"BioNTech SE","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓"},"translate_title":"Survival time has almost doubled! BioNTech (BNTX.US) has successfully completed late-stage trials of its lung cancer drug candidate PRESERVE-003, providing crucial support for its oncology transformation.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CANC":1.5,"BNTX":1.5},"content_text":"【生存期幾乎翻倍！BioNTech(BNTX.US)肺癌候選藥PRESERVE-003後期試驗告捷，腫瘤學轉型再獲關鍵支撐】智通財經APP獲悉，BioNTech(BNTX.US)周一表示，一項後期臨床試驗顯示，其候選藥物gotistobart在一種特定類型肺癌中，較標準治療帶來具有臨床意義的總生存期獲益。公司稱，該試驗為PRESERVE-003 \n\nIII期臨床試驗，納入的是在接受既往免疫治療和化療後疾病仍出現進展的鱗狀非小細胞肺癌患者;與標準治療化療相比，gotistobart使生存期幾乎翻倍。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}